Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Authorised, recruitment pending
Participants planned
40
Countries
1
Sites
1
Post-bariatric hypoglycaemia
Key facts
- Sponsor
- Recordati AG
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Hormonal diseases [C19]
- Decision date (initial)
- 2026-02-23
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- Yes
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Post-bariatric hypoglycaemia
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 21.1 | PT | 10059035 | Postprandial hypoglycaemia | 100000004861 |
| 21.1 | PT | 10077216 | Hyperinsulinaemic hypoglycaemia | 100000004861 |
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Recordati AG
- Sponsor organisation
- Recordati AG
- Address
- Uferstrasse 90
- City
- Basel Town
- Postcode
- 4057
- Country
- Switzerland
Scientific contact point
- Organisation
- Recordati AG
- Contact name
- Arnd Mueller
Public contact point
- Organisation
- Recordati AG
- Contact name
- Recordati AG Clinical Trial Information Desk
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Germany | Authorised, recruitment pending | 40 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2025-12-17 | Germany | Acceptable 2026-02-18
|
2026-02-23 |